NASDAQ · VALN
Healthcare · Biotechnology
$6.55
Up+$0.02 (+0.31%)
Updated Sep 17, 2026, 1:29 AM
SID Score
3.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 19 trading sessions · Daily adjusted prices
VALN closed at $6.55 after 19 trading sessions, down 4.24% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $6.64 | $6.64 | $6.48 | $6.55 | 23.79K |
| Sep 14, 2026 | $6.65 | $6.80 | $6.54 | $6.67 | 13.4K |
| Sep 11, 2026 | $6.77 | $6.80 | $6.54 | $6.66 | 36.61K |
| Sep 10, 2026 | $6.64 | $6.8375 | $6.60 | $6.69 | 46.68K |
| Sep 9, 2026 | $6.80 | $6.8799 | $6.68 | $6.68 | 24.12K |
| Sep 8, 2026 | $6.72 | $7.02 | $6.672 | $6.85 | 28.33K |
| Sep 4, 2026 | $6.92 | $7.00 | $6.87 | $6.89 | 22.87K |
| Sep 3, 2026 | $7.11 | $7.19 | $6.9748 | $7.06 | 40.87K |
| Sep 2, 2026 | $6.80 | $7.15 | $6.80 | $7.12 | 137.18K |
| Sep 1, 2026 | $6.60 | $6.71 | $6.4301 | $6.57 | 27.43K |
| Aug 31, 2026 | $6.35 | $6.3817 | $6.29 | $6.30 | 11.55K |
| Aug 28, 2026 | $6.55 | $6.58 | $6.43 | $6.43 | 22.29K |
| Aug 27, 2026 | $6.66 | $6.66 | $6.54 | $6.56 | 21.5K |
| Aug 26, 2026 | $6.79 | $6.80 | $6.56 | $6.695 | 28.24K |
| Aug 25, 2026 | $6.72 | $6.95 | $6.70 | $6.78 | 30.97K |
| Aug 24, 2026 | $6.68 | $6.7999 | $6.60 | $6.75 | 22.21K |
| Aug 21, 2026 | $6.77 | $7.0586 | $6.7127 | $6.96 | 21.59K |
| Aug 20, 2026 | $6.85 | $6.8999 | $6.69 | $6.82 | 31.05K |
| Aug 19, 2026 | $7.04 | $7.1021 | $6.84 | $6.84 | 74.42K |
The latest Smart Investors Daily articles mentioning VALN.
VALN research
Company profile and research snapshot.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 12, 2026 | FIRST BERLIN EQUITY RESEARCH | Buy | — |
| Jun 28, 2026 | PORTZAMPARC BNP PARIBAS | Buy | — |
| May 12, 2026 | ODDO BHF | Buy | — |
| May 12, 2026 | STIFEL EUROPE | Buy | — |
| Jan 21, 2026 | FIRST BERLIN EQUITY RESEARCH | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 15, 2026
Pfizer Inc. (NYSE:PFE) and Valneva SE (NASDAQ:VALN) reported on August 14 that the European Medicines Agency has validated the Marketing Authorization Application for PF-07307405, the companies’ experimental Lyme disease vaccine candidate, and will now begin the official review. For a vaccine candidate first proposed in a 2020 collaboration deal between Pfizer Inc. (NYSE:PFE) and French […]
Yahoo · Sep 7, 2026
Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Vaccines Market Distribution by Type of Vaccine API, Targeted Patient Population, Type of Vaccines, Route of Administration, and Key Geographical Region - Trends and Forecasts Till 2035" has been added to ResearchAndMarkets.com's offering. The global vaccines market is projected to increase from approximately USD 48 billion to USD 94 billion by 2030, representing a compound annual growth rate of about 11.9% during the forecast period. Market expans
Yahoo · Sep 4, 2026
VALNEVA Declaration of shares and voting rights Status as of August 31, 2026__________________________________________________________________________________________ Company name: VALNEVARegistered office: Îlot Saint-Joseph Bureaux Convergence – Bât. A, 12 ter Quai Perrache – 69002 LyonRegulated market of Euronext Paris - Compartment B Declaration date: September 4, 2026 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Descri
Benzinga · Feb 19, 2026
Total Revenues of €174.7 million in line with guidance, including €157.9 million in product salesStrong year-end cash position of €109.7 million, with enhanced financial flexibility following successful debt
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning VALN.
